HC Wainwright Reiterates Buy Rating for Tyra Biosciences (NASDAQ:TYRA)

HC Wainwright reaffirmed their buy rating on shares of Tyra Biosciences (NASDAQ:TYRA - Free Report) in a research report released on Tuesday,Benzinga reports. HC Wainwright currently has a $30.00 price target on the stock.

A number of other equities research analysts have also recently issued reports on TYRA. Wedbush reiterated an "outperform" rating and set a $28.00 target price on shares of Tyra Biosciences in a research report on Friday, October 25th. UBS Group started coverage on shares of Tyra Biosciences in a research report on Tuesday, January 7th. They set a "buy" rating and a $28.00 target price for the company. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Tyra Biosciences presently has an average rating of "Buy" and a consensus target price of $30.50.

Tyra Biosciences Trading Up 3.1 %

Shares of Tyra Biosciences stock traded up $0.39 during mid-day trading on Tuesday, reaching $13.17. 202,649 shares of the stock were exchanged, compared to its average volume of 265,666. The company has a market cap of $666.40 million, a price-to-earnings ratio of -8.18 and a beta of 1.05. The firm has a 50-day simple moving average of $14.48 and a 200 day simple moving average of $18.18. Tyra Biosciences has a fifty-two week low of $11.89 and a fifty-two week high of $29.60.

Insider Buying and Selling at Tyra Biosciences

In related news, Director Nina S. Kjellson sold 7,779 shares of Tyra Biosciences stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $16.29, for a total transaction of $126,719.91. Following the transaction, the director now owns 447,857 shares of the company's stock, valued at $7,295,590.53. This trade represents a 1.71 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In the last 90 days, insiders sold 21,998 shares of company stock worth $344,818. 15.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. KLP Kapitalforvaltning AS bought a new position in Tyra Biosciences in the fourth quarter valued at approximately $31,000. US Bancorp DE bought a new position in Tyra Biosciences in the fourth quarter valued at approximately $50,000. BNP Paribas Financial Markets bought a new position in Tyra Biosciences in the fourth quarter valued at approximately $60,000. Aquatic Capital Management LLC bought a new position in Tyra Biosciences in the fourth quarter valued at approximately $64,000. Finally, Wells Fargo & Company MN lifted its position in shares of Tyra Biosciences by 51.7% in the fourth quarter. Wells Fargo & Company MN now owns 9,493 shares of the company's stock worth $132,000 after purchasing an additional 3,236 shares in the last quarter. Institutional investors own 84.14% of the company's stock.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.